The study introduces TME Panel-1, an RNA-based diagnostic panel developed by OncXerna Therapeutics in collaboration with Genialis, designed to classify colorectal cancer (CRC) patients based on tumor microenvironment (TME) phenotypes. The panel identifies four phenotypes: Angiogenic (A), Immune Suppressed (IS), Immune Active (IA), and Immune Desert (ID). Results from 657 samples demonstrated that these phenotypes align with known CRC characteristics, including disease stage and tumor side, and are prognostic for recurrence-free and overall survival. TME Panel-1 offers a predictive tool for optimizing CRC treatment strategies and guiding precision medicine.
Published at AACR 2021.
Rafael Rosengarten1, Kristen Strand-Tibbitts2, Valerie Santos2, Julia Carter3, Larry Douglass3, Robert Cvitkovič1, Miha Štajdohar1, Laura Benjamin2
1 Genialis, Inc., Boston, MA
2 OncXerna Therapeutics, Inc., Waltham, MA
3 Wood Hudson Cancer Research Laboratory, Newport, KY
